Market Insights – Global Cannabis Testing Market
Cannabis drug testing refers to drug test methodologies for the use of cannabis in medicine, law or sport. Cannabis are highly detectable and can be detected with urinalysis, hair analysis, and saliva tests for days or weeks. All these tests are done to determine medical potency of the cannabis. It is also tested for determining various other ingredient in given sample. For instance, to determine the pesticide residue content in the given sample that undermines the purity and efficacy. Cannabis testing also involves determination of contaminants such as fungi and bacteria (mycotoxins), which could causes serious pulmonary infections if administered unchecked.
Furthermore, cannabis testing comprises determination of trace metals such as cadmium, arsenic, leads and mercury over cannabis plants and products, which could impart adverse effect to human health. There are three species of cannabis present with each having different concentration of active ingredient. These species can be subjected to risk of adulteration with cannabis species having lower amount of active ingredient. Therefore in such cases cannabis testing would be beneficial to find the authenticity of given specimen.
Request for the trending sample of this report: https://www.coherentmarketinsights.com/insight/request-sample/170
Overall cannabis testing process involves sample and column preparation, identification of analyte, determining concentration, and separating the analyte. Various analytical techniques are used to test the cannabis such as Liquid Chromatography (LC) / High Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), Thin Layer Chromatography (TLC), ELISA kits, and Polymerase Chain Reaction (PCR). Various equipment are used for cannabis testing including breathe analyzer and other instruments, in order to check concentration of tetrahydrocannabinol when consumed illegally. Tetrahydrocannabinol is psychoactive ingredient.
The global cannabis testing market size was valued at US$ 926.3 million in 2017, and is expected to witness a CAGR of 13.2% over the forecast period (2018 – 2026).
Figure 1. Global Cannabis Testing Market (US$ Mn), by Region, 2017
Source: Coherent Market Insights (2018)
Figure 2. Global Cannabis Testing Market (US$ Mn), by Products, 2017
Source: Coherent Market Insights (2018)
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/170
Legalization of cannabis for medicinal and recreational activity to drive growth of the global cannabis testing market
Increasing approval of medicinal cannabis products along with extensive research and development activities in the medical cannabis market are expected to drive growth of the global cannabis testing market during the forecast period.
For instance, in July 2017, 18 states in the U.S. allowed the use of Cannabidiol (CBD) extract, majorly in oil form with minimal tetrahydrocannabinol (THC) for the treatment of epilepsy or seizures in adversely affected children. In March 2017, German parliament signed and enforced law, which allows the healthcare professionals to prescribe the medicinal cannabis products to relieve patients from severe health issues such as chronic pain, vomiting, and nausea.
Moreover, requirement of desired active ingredient detection and undesired trace elements (mycotoxins and trace metals) before utilizing cannabis product for medicinal and recreational purpose are expected to drive growth of the global cannabis testing market during the forecast period. Increased trend of using cannabis for recreational purpose would be another major impetus for simultaneous rise in global cannabis testing market.
In 2012, only two states in the U.S. had legalized recreational use of cannabis however by 2017, seven more states legalized recreational use of cannabis. In January 2018, use of cannabis for recreational purpose initiated in California which resulted in tourist attraction in California and in turn it also doubled the cannabis cultivation assessing business opportunity.
Furthermore, laws mandate compulsory cannabis quality control testing, which is expected to fuel market growth. Furthermore, increasing number of test laboratory across developed country such as U.S. is expected to fuel market growth. First cannabis testing lab was started in Washington U.S. in June 201. ,
Increased approval for cannabis-based drugs and new product launches for cannabis testing are expected to propel growth of the global cannabis testing market
Various cannabis manufacturer across globe are focused on introducing the cannabis products to target various disease, which in turn is expected to promote application of cannabis testing instruments, as this products need to be approved from the health regulatory bodies for their efficacy and purity. For instance, in May 2018, the U.S Food and Drug Administration (FDA) approved the medication, called Epidiolex manufactured by GW Pharmaceuticals to treat two rare forms of epilepsy caused by Lennox-Gastaut and Dravet syndromes in patients two years and older.
In July 2016, Insys Therapeutics, Inc. received U.S.FDA approval for dronabinol oral solution- Syndros, which is an orally administered liquid formulation of cannabinoid dronabinol. The Syndros is indicated for treatment of anorexia associated with weight loss among patients suffering from AIDS and patients suffering from cancer chemotherapy-induced nausea and vomiting.
Key companies in the market are involved in launching innovative, cannabis testing platform, in order to gain competitive edge in the market. For instance, in 2017, Agilent Technologies Inc. launched a high-resolution, accurate gas chromatography mass system named as Agilent 7250 GC/Q-TOF system, which combines gas chromatography and quadrupole time-of-flight mass spectrometry with a Low Energy Electron Ionization source enabling high exploration of unknown chemical samples.
Market Dynamics- Restraints
High cost of analytical instruments for testing cannabis along with lack standards for various residue and unwanted material in cannabis such as pesticide residue, heavy metal, and mycotoxin, which results into inauthenticity of test results given by different cannabis testing laboratories are expected to restrain growth of the global cannabis testing market in the near future.
Key players operating in the global cannabis testing market are Shimadzu Corporation, Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Millipore Sigma, AB SCIEX LLC, Cannabix Technologies, Inc., Waters Corporation, Steep Hill Labs, Inc., CannaSafe Analytics, Accelerated Technology Laboratories, Inc., LabLynx, Inc., SC Laboratories Inc., GenTech Scientific, Pharm Labs, LLC, and Digipath Labs, Inc.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027